Intellect Neurosciences : Notice of Allowance for Patent on Alzheimer's Drug from the Israeli Patent and Trademark Office

June 9, 2010 / Intellect Neurosciences, Inc (OTCBB: ILNS) announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON™), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1, which has been successfully tested by the Company in human Phase I safety trials, is an orally-administered, brain-penetrating, naturally-occurring copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease... Intellect Neurosciences' Press Release -

Intellect Neurosciences : Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

July 31, 2008 - Intellect Neurosciences, Inc. (ILNS) announced it has obtained a European patent relating to the Company's ANTISENILIN® monoclonal antibody platform for the treatment of Alzheimer's disease. The claims of the issued patent cover the ANTISENILIN® "free-end specific" antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer's disease. The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer's patients while reducing the potential for adverse side-effects.
Importantly, such drugs avoid binding and thereby potentially interfering with the functions of the Amyloid Precursor Protein, which is an important physiological regulator in the body implicated in controlling essential brain functions as well as blood coagulation.

The Company recently disclosed that it has granted a royaltybearing license to Wyeth and Elan Pharma International Ltd. regarding patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease, including Bapineuzumab, currently in Phase 3 clinical trials... Intellect Neurosciences' Press Release -

Intellect Neurosciences Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.

May 19, 2008 - Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced that it has entered into a license agreement with Wyeth (NYSE: WYE)
and Elan Pharma International Ltd. ("Elan")
regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease. Under the terms of the agreement, Wyeth and Elan may pay Intellect potential future milestone payments and royalties based on sales of potential products, if it is determined that they are covered by patents that issue from Intellect's patent applications... Intellect Neurosciences' Press Release -

Intellect Neurosciences : ... Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer’s Disease

April 11, 2008 - Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer’s Disease

Intellect Neurosciences, Inc (OTCBB: ILNS),announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company’s ANTISENILIN® antibodies and products being developed by the Company for the treatment of Alzheimer’s disease... Intellect Neurosciences' Press Release -